Lisa A Lallos

US Patent:

7037534, May 2, 2006

Filed:

Oct 24, 2002

Appl. No.:

10/280111

Inventors:

Trevor Castor - Arlington MA, US
Lisa Bastiani Lallos - Chelmsford MA, US

Assignee:

Aphios Corporation - Woburn MA

International Classification:

A01N 65/00

US Classification:

424730, 424 941, 424 946, 424450, 435239, 514449

Abstract:

Described herein is an invention that relates to chemiluminescence-directed antiviral activities of natural and synthesized light-sensitive compounds. Methods are described herein for inactivating infectious virus particles outside and inside an organism. These methods incorporate coupling the antiviral activity of various light-sensitive compounds with chemiluminescence directed by native as well as foreign enzymes of the organism and enhanced by the addition of various anti-quenchers and wavelength-shifting compounds. The methods described herein feature light-sensitive compounds with known antiviral activity exhibited in the presence of light.

US Patent:

20030108918, Jun 12, 2003

Filed:

Dec 31, 2002

Appl. No.:

10/236065

Inventors:

Trevor Castor - Arlington MA, US
Petr Ilyinskii - Somerville MA, US
Lisa Lallos - Chelmsford MA, US

International Classification:

A61K039/12
C12N007/00
C12M001/00
C12Q001/68
C12N007/01

US Classification:

435/006000, 424/204100, 435/235100, 435/283100

Abstract:

Presented herein is a description for the manufacturing of inactivated HIV for use in vaccines against AIDS, as well as other inactivated viruses for other infectious diseases. This invention incorporates methods for inactivating infectious virus particles while retaining protein integrity and antigenicity. The methods utilize critical, near-critical or supercritical fluids with or without polar cosolvents. This invention would allow for the creation of HIV vaccines from genetically attenuated HIV strains for a greater degree of product safety, and from combinations of different HIV strains for broader protection. This HIV vaccine manufacturing technology is inexpensive, amenable to large-scale processing and portable, i.e. it can be readily implemented in a host country site. This invention can be utilized for other viral and bacterial infectious diseases, such as influenza and hepatitis.